LIPOPROTEIN(A) AND PREVALENT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN PATIENTS WITH TYPE 2 DIABETES

被引：0
|
作者：
Barkas, F. [1 ]
Koutsogianni, A. [1 ]
Adamidis, P. [1 ]
Anastasiou, G. [1 ]
Sakkou, S. -F. [1 ]
Kyrili, K. [1 ]
Liamis, G. [1 ]
Liberopoulos, E. [2 ]
机构：
[1] Univ Ioannina, Sch Hlth Sci, Dept Internal Med, Fac Med, Ioannnina, Greece
[2] Natl & Kapodistrian Univ Athens, Propaideut Dept Med 1, Sch Med, Athens, Greece
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP160
引用
收藏
页码：E136 / E137
页数：2
相关论文
共 50 条
  • [21] The correlation analysis between serum MSTN and atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus
    董俐
    China Medical Abstracts(Internal Medicine), 2024, 41 (03) : 160 - 161
  • [22] ATHEROSCLEROTIC DISEASE LOCATION AND DISPARITIES IN THE CONTROL AND TREATMENT OF CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES
    Gouni-Berthold, I.
    Bestehorn, K.
    Krone, W.
    Berthold, H. K.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 33 - 33
  • [23] The Prevalence of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes in Jordan: The PACT-MEA Study
    Haddad, Jihad A.
    Annabi, Firas O. Abbas
    Abbasi, Hiba
    Abu Alsamen, Muneer A.
    Ammari, Fawaz L.
    Haddad, Fares H.
    Haddad, Suhair E.
    Jaradat, Mustafa
    Khassawneh, Adi
    Khatib, Nidal
    Magableh, Arabieh
    Al-Mousa, Eyas
    DIABETES THERAPY, 2025, : 899 - 913
  • [24] Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes
    Berthold, H. K.
    Bestehorn, K. P.
    Krone, W.
    Gouni-Berthold, I.
    DIABETIC MEDICINE, 2010, 27 (03) : 303 - 308
  • [25] Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV
    Kim, Joseph M.
    Bhatt, Deepak L.
    Dagogo-Jack, Samuel
    Cherney, David
    Cosentino, Francesco
    McGuire, Darren K.
    Pratley, Richard E.
    Liu, Chih-Chin
    Cater, Nilo B.
    Frederich, Robert
    Mancuso, James P.
    Cannon, Christopher P.
    DIABETES, 2022, 71
  • [26] Atherosclerotic Disease Location Modifies Control and Treatment of Cardiovascular Risk Factors in Patients With Type 2 Diabetes
    Gouni-Berthold, Ioanna
    Bestehorn, Kurt P.
    Krone, Wilhelm
    Berthold, Heiner K.
    CIRCULATION, 2009, 120 (18) : S547 - S547
  • [27] Influence of the location and the extent of atherosclerotic vascular disease on new cardiovascular events in patients with type 2 diabetes
    Gorter, P. M.
    Visseren, F. L. J.
    Algra, A.
    van der Graaf, Y.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 335 - 335
  • [28] Costs of prevalent and incident cardiovascular disease in patients with type 2 diabetes in Scotland using routinely collected data
    McMeekin, P.
    Geue, C.
    Wu, O.
    Mocevic, E.
    Hoxer, C. Stentoft
    Ochs, A.
    McGurnaghan, S.
    Colhoun, H.
    DIABETOLOGIA, 2018, 61 : S115 - S115
  • [29] High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes
    Heier, Martin
    Ofstad, Anne Pernille
    Borja, Mark S.
    Brunborg, Cathrine
    Endresen, Knut
    Gullestad, Lars
    Birkeland, Kdre, I
    Johansen, Odd Erik
    Oda, Michael N.
    ATHEROSCLEROSIS, 2019, 282 : 183 - 187
  • [30] Gender-related and PUFA-related differences in lipoprotein-associated phospholipase A2 levels in patients with type 2 diabetes and atherosclerotic cardiovascular disease
    Hanarz, Maksymilian
    Siniarski, Aleksander
    Golebiowska-Wiatrak, Renata
    Nessler, Jadwiga
    Malinowski, Krzysztof Piotr
    Gajos, Grzegorz
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 33 (06): : 593 - 600
12345